Immunogenetic and Cytokine Profile Alterations in Autism Spectrum Disorder: A Clinical Study

Abstract

Autism Spectrum Disorder (ASD) is a multifactorial neurodevelopmental disorder with complex interactions between genetic susceptibility, immune dysfunction, and environmental influences. Accumulating evidence suggests that immune system abnormalities, particularly cytokine dysregulation, may interact with genetic vulnerability factors to influence neurodevelopmental trajectories. The broad phenotypic variability observed in ASD raises the possibility that distinct immunogenetic mechanisms underlie different clinical presentations. This study was designed to investigate immunogenetic and cytokine profile alterations in children diagnosed with Autism Spectrum Disorder, with particular emphasis on inflammatory mediators and their potential relationship to immune-related pathogenic mechanisms. A clinical case–control framework was employed to assess circulating cytokines, including IL-6, IL-27, IL-37, IL-29, TNF-α, and IFN-γ, alongside immunoglobulin levels (IgG and IgM). Quantitative immunological assays were utilized to determine serum concentrations. The study further explored the theoretical framework of immunogenetic interaction by analyzing cytokine alterations in the context of potential genetic susceptibility and immune pathway activation. Statistical evaluation was conducted to identify significant immunological differences and possible mechanistic associations. Children with ASD exhibited significant cytokine profile alterations, characterized by enhanced pro-inflammatory responses and modified regulatory cytokine activity. Elevated IL-6, TNF-α, and IFN-γ levels suggest persistent immune activation and possible neuroinflammatory signaling. Variations in IL-27 and IL-37 indicate disruption in immune regulatory balance. These findings support the concept that ASD may involve immune-mediated mechanisms influenced by genetic predisposition affecting cytokine signaling pathways. The integration of cytokine data with immunogenetic perspectives highlights a potential mechanistic link between systemic immune alterations and altered neurodevelopment. The present clinical study provides evidence supporting an immunogenetic framework for Autism Spectrum Disorder, wherein cytokine dysregulation may represent both a biological marker and a mechanistic contributor to disease development. Understanding the interplay between immune signaling molecules and genetic vulnerability may facilitate the identification of biologically defined ASD subtypes and open avenues for targeted immunomodulatory interventions